The behind-the-scenes story of Medicare coverage of low-dose CT (LDCT) screening for lung cancer is not the kind that makes page A1 in the major daily newspapers, but maybe it should. Physicians and device makers have lobbied extensively on the issue, as is their right, but I wonder if getting Congress to weigh in on this issue is really a smart move. To start at the beginning, more or less, the Centers for Medicare & Medicaid Services recently opened a coverage analysis for LDCT, and...